For the first time, researchers have associated self-reported disruption and lack of sleep with CSF biomarkers of Alzheimer’s disease (AD) pathology. This article discusses the study design and the novel findings of the study. Although the accumulation of Amyloid beta (A-beta) plaques is a characteristic marker for AD, other biomarkers can assess the pathologies such as neuronal degeneration, inflammation, synaptic dysfunction etc. This recently cross-sectional study, that has been published in the journal of Neurology investigated the impact of poor sleep quality in the late midlife.
Study Design: 101 participants were included in the trial. These participants were cognitively normal with elevated AD risk (family history 73.3%, APOE epsilon 4+). The mean age of the participants was 62.9 and 65% were female. Sleep assessments were done for all the participants and its quality was…
